<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887224</url>
  </required_header>
  <id_info>
    <org_study_id>3151A1-3360</org_study_id>
    <secondary_id>B2061004</secondary_id>
    <nct_id>NCT00887224</nct_id>
  </id_info>
  <brief_title>Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder</brief_title>
  <official_title>A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the long-term efficacy and safety of
      desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive
      Disorder, using a randomized withdrawal design. Randomized withdrawal means that after
      receiving desvenlafaxine succinate sustained release for a predetermined period of time,
      subjects will be selected by chance to either continue receiving the study drug or to be
      withdrawn from the study drug and receive placebo for the remainder of their participation in
      the trial. Subjects will not know to which group they have been assigned.

      The study consists of an up to 14-day screening period followed by an 8-week open-label
      period in which subjects will knowingly receive 50 mg/day of desvenlafaxine succinate
      sustained release. Subjects who do not respond to treatment, demonstrating no significant
      change in their depressive symptoms, will be withdrawn from participation at the end of this
      period. Responding subjects will receive an additional 3 months of open-label desvenlafaxine
      succinate sustained release at the same dose. Subjects with stable response to treatment at
      the conclusion of this 3 month period will be randomized to either desvenlafaxine succinate
      sustained release at 50 mg/day or placebo in a blinded manner for an additional 6 months or
      until symptoms of depression return. Following discontinuation at any point after enrollment
      in the study, subjects will receive two weeks of follow-up monitoring, including one week of
      blinded taper with 25 mg/day of desvenlafaxine succinate sustained release treatment for any
      subjects who have been taking desvenlafaxine succinate sustained release prior to
      discontinuation. Subjects assigned to placebo will receive a blinded placebo taper. Following
      taper, subjects will be evaluated for one additional week to monitor safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185</measure>
    <time_frame>Double-blind phase Baseline (Study Day 140) up to DB Day 185 (Study Day 325)</time_frame>
    <description>Time to relapse analyzed using log-rank test; defined as Hamilton Psychiatric Scale for Depression-17 item score ≥16 at any time during DB phase, discontinuation for unsatisfactory response or efficacy (need for additional or alternate treatment for depression, investigator decision to remove participant for efficacy reasons, or failure to return if investigator determined related to efficacy), hospitalization for depression, suicide attempt, or suicide. Participants who relapsed after DB day 185 or completed DB therapy without relapse were considered as censored on DB day 185 (study day 325).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Per Categorical Score for Change From Baseline on Clinical Global Impression-Improvement (CGI-I) Scale</measure>
    <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
    <description>CGI-I is a 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score in the Double-blind Phase</measure>
    <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
    <description>CGI-S is a 7-point clinician rated scale to assess severity of participant's current illness state; range of 1 (normal - not ill at all) to 7 (among the most extremely ill). Higher score = more affected. Change from baseline mean=adjusted mean change calculated using mixed-effects model for repeated measures (MMRM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score in the Double-blind Phase</measure>
    <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
    <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression. Change from baseline mean=adjusted mean change calculated using MMRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hamilton Psychiatric Scale for Depression-6 Item (HAM-D6) Score in the Double-blind Phase</measure>
    <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
    <description>HAM-D6 is a standardized, clinician-administered rating scale is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 (0=none/absent to 2=most severe) and all others are scored 0 to 4 (0=none/absent to 4=most severe). Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline mean=adjusted mean change calculated using MMRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Remission Based on Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score at Double-blind Phase Week 26</measure>
    <time_frame>Double-blind phase Week 26 (Study Day 322)</time_frame>
    <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression. Remission defined as HAM-D17 total score ≤7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Double-blind Phase in World Health Organization (Five-Item) Well-Being Index</measure>
    <time_frame>Double-blind phase Baseline (Study Day 140), Week 14 (Study Day 238), Week 26 (Study Day 322)</time_frame>
    <description>WHO-5 evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions (felt cheerful, in good spirits; felt calm, relaxed; felt active, vigorous; woke up fresh, rested; and daily life filled with things that are interesting) each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score ranged from 0 (worst possible quality of life) to 25 (best possible quality of life). Change from baseline mean=adjusted mean change calculated using MMRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score in the Double-blind Phase</measure>
    <time_frame>Double-blind phase Baseline (Study Day 140), Week 14 (Study Day 238), Week 26 (Study Day 322)</time_frame>
    <description>WPAI is a 6 question participant rated questionnaire to determine the degree to which depression affected work productivity while at work and affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher score indicated greater impairment and less productivity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">874</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Desvenlafaxine succinate sustained release 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine succinate sustained release 50 mg</intervention_name>
    <description>50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.</description>
    <arm_group_label>Desvenlafaxine succinate sustained release 50 mg</arm_group_label>
    <other_name>Pristiq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine succinate sustained release 25 mg</intervention_name>
    <description>25 mg tablet for taper, once daily for 1 week</description>
    <arm_group_label>Desvenlafaxine succinate sustained release 50 mg</arm_group_label>
    <other_name>Pristiq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive
             symptoms for at least 30 days prior to screening)

          -  Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of &gt;= 20

          -  Clinical Global Impressions Scale-Severity (CGI-S) score of &gt;= 4.

        Exclusion Criteria:

          -  Significant risk of suicide as assessed by clinician judgment, HAM-D17 and Columbia
             Suicide-Severity Rating Scale scores.

          -  Past treatment with desvenlafaxine succinate sustained release.

          -  Other eligibility criteria also apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 6W6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Medicine Hat</city>
        <state>Alberta</state>
        <zip>T1B 4E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <zip>E2A 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R 4E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 4G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9A 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>7530193</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>7630000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8330838</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucamaranga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>12618</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>51003</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Voru</city>
        <zip>65608</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vöru</city>
        <zip>65608</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <zip>80100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dole</city>
        <zip>39100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Douai</city>
        <zip>59500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orvault</city>
        <zip>44700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liepaja</city>
        <zip>LV-3400</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sigulda</city>
        <zip>LV-2150</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sigulda</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Strenci</city>
        <zip>4730</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>3000</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50185</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vilius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>10204</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09112</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10204</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Skorzewo</city>
        <state>Poznan</state>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-460</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tuszyn</city>
        <zip>95-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-227</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zuromin</city>
        <zip>09-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200317</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>041914</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>041914</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400012</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bojnice</city>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>820 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <zip>031 23</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Michalovce</city>
        <zip>071 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>979 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>91101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durban</city>
        <zip>3630</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paarl</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3151A1-3360&amp;StudyName=Relapse%20Prevention%20Study%20Of%20Desvenlafaxine%20Succinate%20Sustained%20Release%20In%20Outpatients%20With%20Major%20Depressive%20Disorder</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <results_first_submitted>March 6, 2012</results_first_submitted>
  <results_first_submitted_qc>May 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2012</results_first_posted>
  <last_update_submitted>November 6, 2014</last_update_submitted>
  <last_update_submitted_qc>November 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1072 participants were screened, 874 were enrolled into Desvenlafaxine succinate sustained release (DVS SR) open-label 8-week response phase; 659 entered into 12-week open label stability phase. After 20 weeks of open-label treatment 548 subjects were randomized to the 6-month double-blind phase to receive either placebo or to continue with DVS SR.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DVS SR 50 mg (Open-label Phase)</title>
          <description>Desvenlafaxine succinate sustained release (DVS SR) 50 milligrams (mg) by mouth (PO) once daily (QD) for 20 weeks (Days 1 to 140). This included an 8-week response phase and for responders at Week 8, a 12-week stability phase. Participants who concluded open-label study or discontinued treatment received DVS SR 25 mg PO QD for 7-day taper period (All Enrolled Population).</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Double-blind Phase)</title>
          <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD (All Randomized Population).</description>
        </group>
        <group group_id="P3">
          <title>DVS SR 50 mg (Double-blind Phase)</title>
          <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD (All Randomized Population).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Response (OLR) Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="874"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="752"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Between OLR and OLS Phases</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="752"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="659"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-label Stability (OLS) Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="659"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="576"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Between OLS and DB Phases</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="576"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="548"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>OL Taper Phase / OL Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="307">Could have entered 7-day taper period at any time during either the OLR phase or OLS phase.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Open-label Taper</title>
              <participants_list>
                <participants group_id="P1" count="144">Could have discontinued at any time during OL taper phase or OL Follow-up (7 days after last dose).</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind (DB) Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="276">2 participants randomized in error to DB, then entered OL Taper; counted in OL Taper and DB phases.</participants>
                <participants group_id="P3" count="272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>DB Taper Phase / Post Study Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="267">Double-blind participants (DBp) could have entered 7-day taper period at any time during DB phase.</participants>
                <participants group_id="P3" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Did Not Enter DB Taper</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued DB Taper</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="41">DBp could have discontinued at anytime during DB taper period or Follow-up (7 days after last dose).</participants>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DVS SR 50 mg (Open-label Phase)</title>
          <description>DVS SR 50 mg PO QD for 20 weeks (Days 1 to 140). This included an 8-week response phase and for responders at Week 8, a 12-week stability phase. Participants who concluded open-label study or discontinued treatment received DVS SR 25 mg PO QD for 7-day taper period (All Enrolled Population).</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Double-blind Phase)</title>
          <description>Eligible participants from OL Phase were randomized in a 1:1 ratio to either Placebo or DVS SR in the DB Phase.
Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD (All Randomized Population).</description>
        </group>
        <group group_id="B3">
          <title>DVS SR 50 mg (Double-blind Phase)</title>
          <description>Eligible participants from OL Phase were randomized in a 1:1 ratio to either Placebo or DVS SR in the DB Phase.
DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD (All Randomized Population).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="874"/>
            <count group_id="B2" value="276"/>
            <count group_id="B3" value="272"/>
            <count group_id="B4" value="1422"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>OL Baseline All Enrolled Population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.98" spread="13.25"/>
                    <measurement group_id="B2" value="NA">Baseline Age reported for participants entering the Open-label phase at study start.</measurement>
                    <measurement group_id="B3" value="NA">Baseline Age reported for participants entering the Open-label phase at study start.</measurement>
                    <measurement group_id="B4" value="44.98" spread="13.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>OL Baseline All Enrolled Population. Baseline Gender reported for participants entering the Open-label phase at study start.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="608"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants per categorical score on Clinical Global Impression-Improvement (CGI-I) scale</title>
          <description>CGI-I is a 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Outcome measure CGI-I results reported for DB phase; CGI-I baseline=DB baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="223"/>
                    <measurement group_id="B4" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Total Score</title>
          <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Outcome measure HAM-D17 results reported for DB phase; HAM-D17 baseline=DB baseline.</measurement>
                    <measurement group_id="B2" value="4.58" spread="3.02"/>
                    <measurement group_id="B3" value="4.69" spread="2.97"/>
                    <measurement group_id="B4" value="4.64" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with remission based on HAM-D17 score</title>
          <description>HAM-D17: standardized, clinician-administered rating scale that assesses 17 items associated with major depression (such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items scored on 3 point scale (0=none/absent to 2=most severe) and 8 items scored on 5 point scale (0=none/absent to 4=most severe) for maximum total score of 50; higher score indicates more depression. Remission (Yes or No) based on HAMD-17 total score ≤7. Outcome measure HAM-D17 Remission results reported for DB phase; HAM-D17 Remission baseline=DB baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Remission=No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission=Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="220"/>
                    <measurement group_id="B4" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185</title>
        <description>Time to relapse analyzed using log-rank test; defined as Hamilton Psychiatric Scale for Depression-17 item score ≥16 at any time during DB phase, discontinuation for unsatisfactory response or efficacy (need for additional or alternate treatment for depression, investigator decision to remove participant for efficacy reasons, or failure to return if investigator determined related to efficacy), hospitalization for depression, suicide attempt, or suicide. Participants who relapsed after DB day 185 or completed DB therapy without relapse were considered as censored on DB day 185 (study day 325).</description>
        <time_frame>Double-blind phase Baseline (Study Day 140) up to DB Day 185 (Study Day 325)</time_frame>
        <population>All Randomized population: all participants randomly assigned to the Double-blind treatment phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185</title>
          <description>Time to relapse analyzed using log-rank test; defined as Hamilton Psychiatric Scale for Depression-17 item score ≥16 at any time during DB phase, discontinuation for unsatisfactory response or efficacy (need for additional or alternate treatment for depression, investigator decision to remove participant for efficacy reasons, or failure to return if investigator determined related to efficacy), hospitalization for depression, suicide attempt, or suicide. Participants who relapsed after DB day 185 or completed DB therapy without relapse were considered as censored on DB day 185 (study day 325).</description>
          <population>All Randomized population: all participants randomly assigned to the Double-blind treatment phase of the study.</population>
          <units>percent estimated probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance declared if p-value ≤0.05. The estimated probability obtained via Kaplan-Meier estimate.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Per Categorical Score for Change From Baseline on Clinical Global Impression-Improvement (CGI-I) Scale</title>
        <description>CGI-I is a 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.</description>
        <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
        <population>All Randomized population. N=number of participants with analyzable data at observation (Observed Cases).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD..</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Per Categorical Score for Change From Baseline on Clinical Global Impression-Improvement (CGI-I) Scale</title>
          <description>CGI-I is a 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.</description>
          <population>All Randomized population. N=number of participants with analyzable data at observation (Observed Cases).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DB Week 1: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 1: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 1: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 1: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 1: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 1: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 1: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 2: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 2: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 2: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 2: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 2: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 2: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 2: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 3: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 3: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 3: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 3: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 3: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 3: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 3: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 4: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 4: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 4: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 4: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 4: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 4: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 4: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 6: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 6: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 6: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 6: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 6: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 6: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 6: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 10: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 10: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 10: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 10: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 10: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 10: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 10: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 14: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 14: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 14: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 14: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 14: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 14: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 14: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 18: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 18: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 18: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 18: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 18: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 18: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 18: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 22: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 22: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 22: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 22: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 22: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 22: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 22: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 26: 1=very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 26: 2=much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 26: 3=minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 26: 4=no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 26: 5=minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 26: 6=much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DB Week 26: 7=very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score in the Double-blind Phase</title>
        <description>CGI-S is a 7-point clinician rated scale to assess severity of participant's current illness state; range of 1 (normal - not ill at all) to 7 (among the most extremely ill). Higher score = more affected. Change from baseline mean=adjusted mean change calculated using mixed-effects model for repeated measures (MMRM).</description>
        <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
        <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score in the Double-blind Phase</title>
          <description>CGI-S is a 7-point clinician rated scale to assess severity of participant's current illness state; range of 1 (normal - not ill at all) to 7 (among the most extremely ill). Higher score = more affected. Change from baseline mean=adjusted mean change calculated using mixed-effects model for repeated measures (MMRM).</description>
          <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at DB Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.03"/>
                    <measurement group_id="O2" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.04"/>
                    <measurement group_id="O2" value="0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.04"/>
                    <measurement group_id="O2" value="0.07" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.05"/>
                    <measurement group_id="O2" value="0.06" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.05"/>
                    <measurement group_id="O2" value="0.06" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.06"/>
                    <measurement group_id="O2" value="0.11" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.05"/>
                    <measurement group_id="O2" value="0.05" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.06"/>
                    <measurement group_id="O2" value="0.09" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.07"/>
                    <measurement group_id="O2" value="0.13" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.06"/>
                    <measurement group_id="O2" value="0.09" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9627</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1046</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0228</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 18</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 22</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score in the Double-blind Phase</title>
        <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression. Change from baseline mean=adjusted mean change calculated using MMRM.</description>
        <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
        <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score in the Double-blind Phase</title>
          <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression. Change from baseline mean=adjusted mean change calculated using MMRM.</description>
          <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at DB Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.17"/>
                    <measurement group_id="O2" value="0.25" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.24"/>
                    <measurement group_id="O2" value="0.53" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.22"/>
                    <measurement group_id="O2" value="0.45" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.24"/>
                    <measurement group_id="O2" value="0.11" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.28"/>
                    <measurement group_id="O2" value="0.31" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="0.32"/>
                    <measurement group_id="O2" value="0.69" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.30"/>
                    <measurement group_id="O2" value="0.62" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="0.33"/>
                    <measurement group_id="O2" value="0.56" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.37"/>
                    <measurement group_id="O2" value="0.92" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at DB Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="0.36"/>
                    <measurement group_id="O2" value="0.77" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8853</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0081</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 18</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 22</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>3.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>3.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hamilton Psychiatric Scale for Depression-6 Item (HAM-D6) Score in the Double-blind Phase</title>
        <description>HAM-D6 is a standardized, clinician-administered rating scale is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 (0=none/absent to 2=most severe) and all others are scored 0 to 4 (0=none/absent to 4=most severe). Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline mean=adjusted mean change calculated using MMRM.</description>
        <time_frame>Double-blind phase Baseline (Study Day 140) up to Week 26 (Study Day 322)</time_frame>
        <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hamilton Psychiatric Scale for Depression-6 Item (HAM-D6) Score in the Double-blind Phase</title>
          <description>HAM-D6 is a standardized, clinician-administered rating scale is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 (0=none/absent to 2=most severe) and all others are scored 0 to 4 (0=none/absent to 4=most severe). Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline mean=adjusted mean change calculated using MMRM.</description>
          <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at DB Week1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.10"/>
                    <measurement group_id="O2" value="0.01" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.14"/>
                    <measurement group_id="O2" value="0.13" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.14"/>
                    <measurement group_id="O2" value="0.14" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.15"/>
                    <measurement group_id="O2" value="0.03" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.17"/>
                    <measurement group_id="O2" value="0.16" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.19"/>
                    <measurement group_id="O2" value="0.33" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.17"/>
                    <measurement group_id="O2" value="0.34" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.20"/>
                    <measurement group_id="O2" value="0.21" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.20"/>
                    <measurement group_id="O2" value="0.45" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.20"/>
                    <measurement group_id="O2" value="0.26" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9142</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0069</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 18</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 22</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Remission Based on Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score at Double-blind Phase Week 26</title>
        <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression. Remission defined as HAM-D17 total score ≤7.</description>
        <time_frame>Double-blind phase Week 26 (Study Day 322)</time_frame>
        <population>All Randomized population. N=number of participants with analyzable data at observation based on Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Remission Based on Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score at Double-blind Phase Week 26</title>
          <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression. Remission defined as HAM-D17 total score ≤7.</description>
          <population>All Randomized population. N=number of participants with analyzable data at observation based on Last Observation Carried Forward (LOCF).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Wald 95% CI for adjusted odds ratio.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Obtained from logistic regression analysis using Remission (Yes/No) at each time point as a response variable; logistic model with treatment and sites as factors and baseline HAM-D17 total score as covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Adjusted odds ratio</param_type>
            <param_value>2.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>4.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Double-blind Phase in World Health Organization (Five-Item) Well-Being Index</title>
        <description>WHO-5 evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions (felt cheerful, in good spirits; felt calm, relaxed; felt active, vigorous; woke up fresh, rested; and daily life filled with things that are interesting) each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score ranged from 0 (worst possible quality of life) to 25 (best possible quality of life). Change from baseline mean=adjusted mean change calculated using MMRM.</description>
        <time_frame>Double-blind phase Baseline (Study Day 140), Week 14 (Study Day 238), Week 26 (Study Day 322)</time_frame>
        <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Double-blind Phase in World Health Organization (Five-Item) Well-Being Index</title>
          <description>WHO-5 evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions (felt cheerful, in good spirits; felt calm, relaxed; felt active, vigorous; woke up fresh, rested; and daily life filled with things that are interesting) each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score ranged from 0 (worst possible quality of life) to 25 (best possible quality of life). Change from baseline mean=adjusted mean change calculated using MMRM.</description>
          <population>All Randomized population. N=number of participants with analyzable data at observation.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at DB Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="0.35"/>
                    <measurement group_id="O2" value="-0.38" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at DB Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="0.38"/>
                    <measurement group_id="O2" value="-0.04" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.29</ci_lower_limit>
            <ci_upper_limit>-1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score in the Double-blind Phase</title>
        <description>WPAI is a 6 question participant rated questionnaire to determine the degree to which depression affected work productivity while at work and affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher score indicated greater impairment and less productivity.</description>
        <time_frame>Double-blind phase Baseline (Study Day 140), Week 14 (Study Day 238), Week 26 (Study Day 322)</time_frame>
        <population>All Randomized population. Change from baseline (Bsl) mean=adjusted mean change calculated using MMRM.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 50 mg</title>
            <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score in the Double-blind Phase</title>
          <description>WPAI is a 6 question participant rated questionnaire to determine the degree to which depression affected work productivity while at work and affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combined absenteeism and presenteeism and percentage of impairment in activities performed outside of work. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher score indicated greater impairment and less productivity.</description>
          <population>All Randomized population. Change from baseline (Bsl) mean=adjusted mean change calculated using MMRM.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Bsl at DB Week 14: Absenteeism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="1.72"/>
                    <measurement group_id="O2" value="0.62" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Bsl at DB Week 14: Presenteeism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="2.30"/>
                    <measurement group_id="O2" value="2.44" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Bsl DB Week 14: Work productivity loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.66" spread="2.48"/>
                    <measurement group_id="O2" value="2.19" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Bsl at DB Week 14: Activity impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.02" spread="1.62"/>
                    <measurement group_id="O2" value="3.45" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Bsl at DB Week 26: Absenteeism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="2.05"/>
                    <measurement group_id="O2" value="0.77" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Bsl at DB Week 26: Presenteeism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="2.35"/>
                    <measurement group_id="O2" value="-0.49" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Bsl DB Week 26: Work productivity loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.47" spread="2.56"/>
                    <measurement group_id="O2" value="-0.00" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Bsl at DB Week 26: Activity impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" spread="1.75"/>
                    <measurement group_id="O2" value="2.05" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14 Absenteeism</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6772</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.82</ci_lower_limit>
            <ci_upper_limit>5.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26 Absenteeism</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9059</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.91</ci_lower_limit>
            <ci_upper_limit>5.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14 Presenteeism</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0414</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>13.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26 Presenteeism</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0129</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>14.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14 Work Productivity Loss</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0402</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>14.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26 Work Productivity Loss</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0187</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>15.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 14 Activity Impairment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.33</ci_lower_limit>
            <ci_upper_limit>11.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted difference from placebo: Week 26 Activity Impairment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value obtained from mixed model: change from baseline = baseline + site + treatment + visit + treatment*visit with &quot;Unstructured&quot; covariance structure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effects model for repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.14</ci_lower_limit>
            <ci_upper_limit>12.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events collected from the time informed consent in Open-Label phase (OL) through 15 days after last dose or up to study day 336.</time_frame>
      <desc>Same event may appear as both an AE and SAE, however, are presented as distinct events; may be categorized as SAE in 1 subject and as non-SAE in another, or 1 subject may have experienced both an SAE and non-SAE during study. Participants are counted multiple times: transition from OL Response to OL Stability phase; then as randomized to DB phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>DVS SR 50 mg (Open-label Response Phase)</title>
          <description>DVS SR 50 mg PO QD for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>DVS SR 50 mg (Open Label Stability Phase)</title>
          <description>DVS SR 50 mg PO QD; Responders at week 8 entered a 12-week stability phase.</description>
        </group>
        <group group_id="E3">
          <title>DVS SR 50 mg (Open Label Taper / OL Post Study Follow Up)</title>
          <description>Participants who concluded DVS SR 50 mg open-label study or discontinued treatment at any time in OLR or OLS could have entered the taper phase and received DVS SR 25 mg PO QD for a 7-day period of taper treatment. N=number of participants with OL Taper or OL Post Study Follow Up emergent events who did not enter the DB Phase and concluded or discontinued with or without taper treatment.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Double-blind Phase)</title>
          <description>Placebo matching DVS SR 50 mg and DVS SR 25 mg PO QD Days 141 to 147, then placebo matching DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with placebo matching DVS SR 25 mg PO QD.</description>
        </group>
        <group group_id="E5">
          <title>DVS SR 50 mg (Double-blind Phase)</title>
          <description>DVS SR 50 mg and placebo matching DVS SR 25 mg PO QD Days 141 to 147; DVS SR 50 mg PO QD Days 148 to 322 followed by 7-day taper period with DVS SR 25 mg PO QD.</description>
        </group>
        <group group_id="E6">
          <title>Placebo (DB Taper / DB Post Study Follow Up)</title>
          <description>Participants who concluded or discontinued placebo during the DB phase could have entered the taper phase and received placebo matching DVS SR 25 mg for a 7-day period of taper treatment. N=number of participants with DB Taper or DB Post Study Follow Up emergent events who concluded or discontinued with or without taper treatment.</description>
        </group>
        <group group_id="E7">
          <title>DVS SR 50 mg (DB Taper / DB Post Study Follow Up)</title>
          <description>Participants who concluded or discontinued DVS SR 50 mg during the DB phase could have entered the taper phase and received DVS SR 25 mg for a 7-day period of taper treatment. N=number of participants with DB Taper or DB Post Study Follow Up emergent events who concluded or discontinued with or without taper treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non−cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Genital infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <description>Outcome: Death</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Intrauterine death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="609" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="874"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="272"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>P-value from the primary analysis is different from the one testing equality of relapse rates on Double-blind day 185. Estimated percentages were provided as representative descriptive measures. Medians were not estimable due to low relapse rates.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

